CorMedix (NASDAQ:CRMD) CEO Joseph Todisco Acquires 80,000 Shares of Stock

CorMedix Inc (NASDAQ:CRMD – Get Free Report) CEO Joseph Todisco acquired 80,000 shares of the stock in a transaction that occurred on Friday, November 13th. The stock was purchased at an average price of $4.89 per share, with a total value of $391,200.00. Following the completion of the transaction, the chief executive officer owned 854,749 shares of the company’s stock, valued at approximately $4,179,722.61. This trade represents a 10.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

CorMedix Stock Performance

Shares of NASDAQ:CRMD opened at $4.82 on Tuesday. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. CorMedix Inc has a 1-year low of $4.65 and a 1-year high of $13.02. The stock has a market capitalization of $375.67 million, a P/E ratio of 3.75, a P/E/G ratio of 0.90 and a beta of 1.48. The business has a 50-day moving average price of $7.11 and a two-hundred day moving average price of $7.55.

CorMedix (NASDAQ:CRMD – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 27.12%. The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. Equities analysts predict that CorMedix Inc will post 0.52 earnings per share for the current year.

Hedge Funds Weigh In On CorMedix

A number of institutional investors have recently added to or reduced their stakes in CRMD. Advisors Asset Management Inc. acquired a new position in shares of CorMedix during the 3rd quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of CorMedix in the 3rd quarter valued at about $31,000. Kestra Advisory Services LLC lifted its stake in CorMedix by 142.9% in the 1st quarter. Kestra Advisory Services LLC now owns 10,200 shares of the company’s stock valued at $69,000 after purchasing an additional 6,000 shares during the last quarter. Quantbot Technologies LP acquired a new stake in CorMedix in the 2nd quarter valued at about $85,000. Finally, Allworth Financial LP acquired a new stake in CorMedix in the 2nd quarter valued at about $88,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Needham & Company LLC increased their price objective on shares of CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. UBS Group set a $19.00 target price on shares of CorMedix in a report on Tuesday, November 10th. Royal Bank Of Canada upped their target price on shares of CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday, November 10th. Wall Street Zen cut shares of CorMedix from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Citigroup reissued a “market outperform” rating on shares of CorMedix in a research note on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.22.

Check Out Our Latest Stock Report on CorMedix

About CorMedix

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Featured Articles

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.